News | Heart Valve Technology | November 09, 2016

Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital Successful

Following 100-patient, multi-center trial, unique approach to aortic valve replacement shows 98 percent success rate

transcaval valve replacement, Henry Ford Hospital, Detroit Michigan, success rate, JACC study, TCT 2016

November 9, 2016 — A pioneering way to access the heart for transcatheter valve replacement has a 98 percent success rate, according to a study published in the Journal of the American College of Cardiology.

Henry Ford Hospital, Detroit, was the first hospital in the United States performing the unique procedure called transcaval valve replacement, which accesses the heart by temporarily connecting major blood vessels in the patient’s abdomen. Cardiologist Adam Greenbaum, M.D., medical co-director of the Center For Structural Heart Disease at Henry Ford Hospital, led the team who performed the first procedure at Henry Ford on July 3, 2013.

Watch a 2017 interview with Greenbaum in the VIDEO: Transcaval Access in TAVR Procedures.

The study, published this week online, reported a 98 percent success rate for the procedure in 100 patients in a multi-center trial. Greenbaum presented the results to interventional cardiologists gathered at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Washington, D.C.

“There were some doubters, so the reason we did this prospective trial was to prove that it could be done safely,” Greenbaum said at the conference focused on catheter-based treatments. “The success of this approach offers a new route for heart valve patients who may be out of options.”

Robert Lederman, M.D., an interventional cardiologist at the National Heart, Lung, and Blood Institute, developed the transcaval technique in a research setting. He came to Henry Ford in July 2013 to observe the initial procedure and share his insights.

Since then, the procedure has been performed when the patients were either too sick for traditional open heart surgery, or their anatomy, like small arteries, prevented the use of more traditional routes to the heart using a catheter.

During transcaval valve replacement, a wire is guided into a leg and up through the femoral vein. An opening between the vein and artery is widened to the point of allowing a catheter to connect them, continue to the heart and implant the new artificial aortic heart valve.
 
As the catheter is removed, plugs are inserted in the artery and the vein to close the holes made for the temporary connection of the two major blood vessels. Greenbaum and the Center for Structural Heart Disease team at Henry Ford Hospital are the most experienced team performing the procedure in the United States.

Northern Michigan resident Viola Waller was 80 years old when she underwent Henry Ford’s first transcaval procedure in 2013 after being told at another hospital her condition was untreatable. The mother of three, grandmother of five and great-grandmother of three now lives in Charlevoix in northern Michigan.

William O’Neill, M.D., medical director of Henry Ford’s Center for Structural Heart Disease, said the procedure could help 25,000 to 50,000 patients annually.

“The milestone brings a message of hope for other potential patients in Michigan and across the country,” said O’Neill.

Approximately 5 million people in the United States are diagnosed with heart valve disease annually. With an aging population that is often too frail for open-heart surgery, more than 20,000 Americans die of the disease each year, according to the American Heart Association.

For more information: www.henryfordhospital.com/structuralheart

 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init